teclistamab
janssen,genmab
['mmsm', 'majestec-1', 'teclistamab']
congress | #eha2022 | cyrille touzeau talks on teclistamab in pts previously treated with a bcma-targeted tx from majestec-1 trial
- orr: 52.5%, early, durable responses deepened over time - mrd neg: 17.5%
- good tolerability w/o dose reductions/discontinuations #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma